Sarawak Shell Bhd (SSB), a subsidiary of Royal Dutch Shell plc, has taken a final investment decision on the Timi gas development project and, together with its partners PETRONAS Carigali Sdn Bhd and Brunei Energy Exploration, look forward to delivering this for Malaysia. The Timi development features SSB’s first wellhead platform in Malaysia that is powered by a solar and wind hybrid renewable power system.
Passport Renewal by Mail
Effective September 1, 2021, eligible adult U.S. passport holders may apply to renew their ten-year passport by mail through Aramex courier service.
Eligibility
Adult U.S. passport holders may renew their ten-year passport and/or passport cards by Aramex courier service if their most recent U.S. passport and/or passport card is:
- Undamaged;
- Issued when the bearer was 16 years old or older;
- Issued within the last 15 years;
- Issued with a 10-year validity; and
- Issued in the bearer’s current name; or if legal documentation of a name change is also submitted.
For more information about renewing U.S. Passport by mail including the steps on how you can apply to renew your passport through Aramex courier service, which documents you must submit, how to pay for this service, and where to obtain a banker’s cheque, please click here.
One-way Delivery Service
Additionally, effective September 1, 2021, U.S. Passport and Consular Report of Birth Abroad (CRBA) applicants who applied in person may opt to receive their new passports and/or CRBAs via Aramex courier service in lieu of returning to the U.S. Embassy a second time to collect the completed passport and/or CRBA.
Please review the Passport Services or CRBA Services page to make your passport or CRBA appointment. On the day of your appointment, notify consular staff that you wish to utilize Aramex delivery service to receive your new passport or CRBA.
For more information about One-Way Delivery Service please click here.
The questions mark rose when Surina Shukri CEO of MDEC stated her decision to leave on who will be driving the agency that will spearhead the nation into the digital era. Well the speculation can be put the rest, with the confirmed appointment of Ts Mahadhir Aziz the founder and CEP of Futurise which is part of Cyberview as the new Chief Executive Officer, effectively.
FedEx Express Malaysia has experienced increased volume demand during the COVID-19 pandemic, driven by the increase of e-commerce purchases among Malaysians, managing director SC Chong said.
Chong said the already booming online purchases trend had gained a renewed momentum with more adoption among customers across the region.
According to the GlobalData’s E-Commerce Analytics, Malaysia’s e-commerce market reported a 24.7 per cent growth in 2020.
As today is the first Wednesday of the month, AMCHAM held its monthly Members’ Briefing virtually once again. This session featured special guests Michael Newbill, Deputy Chief of Mission of the U.S. Embassy in Kuala Lumpur and Ibrahim Suffian, Co-Founder and Program Director of Merdeka Center for Opinion Research.
AMCHAM’s CEO Siobhan Das provided the updates from the Chamber after the mental health break. This includes the upcoming events, government-related engagements on travel and COVID-19 vaccinations and more. Michael Newbill updated the members on initiatives coming from the U.S. side including the recent visit from the Vice President to Singapore and Vietnam and the status of APAC.
Ibrahim Suffian presented on the status of Malaysia particularly the current political landscape, how does the public feel about it and what the likely course could be. AMCHAM members had the opportunity to raise questions and concerns to our special guests as we continue to navigate through the pandemic. Special thanks to both of our special guests for a very informative Members’ Briefing.
Although there is no explicit mention of data exclusivity (DE), Article 39.3 is commonly perceived to be the source of protection extended to pre-existing data generated from big-budget clinical trials and research by innovator companies. DE protects against any commercial use by a third party, usually a company seeking to establish bioequivalence of generic drugs or biosimilars by referencing clinical data of medicinal products to obtain marketing approvals for generics or biosimilars. Under the DE mechanism, these companies may only submit their application which relies on the clinical data generated by innovator companies after the DE period expires.
The DE mechanism is intended and thought to serve as an incentive that encourages development of new drug therapies in a heavily invested research-based industry. It delays generic and biosimilar entries into the market. This allows innovator companies to recoup their often blockbuster investment in drug research and development.
